TIDMOXB

RNS Number : 4456N

Oxford Biomedica PLC

29 September 2021

Directors Dealings / Market Share Purchases

Oxford, UK - 29 September 2021: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that Dr. Michael Hayden, a Non-Executive Director of the Company, has purchased shares in the Company.

As stated in the Oxford Biomedica 2021 Remuneration Policy which was approved at the 2021 Annual General Meeting, an additional fee of up to GBP50,000 per annum may be paid to any Non-Executive Director recruited from or based in the United States to reflect market levels of remuneration in the United States for Non-Executive Directors, subject to their agreement that the after tax amount of this additional fee will be used to acquire Oxford Biomedica shares at market value, which must be retained for at least 12 months from acquisition.

Dr. Hayden has purchased 1,910 ordinary shares of 50p each ("Ordinary Shares") in the Company on 29 September 2021 on the London Stock Exchange at a price of 1507p under the terms of a market purchase agreement. Following this purchase Dr. Hayden holds 1,910 Ordinary Shares representing 0.002% of the Company.

The below notification, made in accordance with the requirements of Article 19 of the Market Abuse Regulation (EU) 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, gives further detail of the ordinary shares purchased.

 
 1.   Details of the person discharging material responsibilities/person 
       closely associated 
 a.   Name                                         Michael Hayden 
 2.   Reason for the notification 
 a.   Position/status                              Non-Executive Director 
 b.   Initial notification                         Initial notification 
       /amendment 
3.    Details of the issuer, emission allowance, market 
       participant, auction platform, auctioneer or auction 
       monitor 
 a.   Name                                         Oxford Biomedica plc 
 b.   Legal Entity Identifier                      213800S1GVQNXQ15K851 
4.    Details of the transaction(s); section to be repeated 
       for (i) each type of instrument; (ii) each type of 
       transaction; (iii) each date; and (iv) each place 
       where transactions have been conducted 
 a.   Description of                               Oxford Biomedica plc Ordinary Shares 
       the financial                                of 50p each 
       instrument, type                             GB00BDFBVT43 
       of instrument 
       identification 
       code 
b.    Nature of the                                Purchase of ordinary shares 
       transaction 
c.    Currency                                     GBP - British Pound 
d.    Price(s) and volume(s)                             Price(s)               Volume(s) 
                                GBP15.075                                         1,910 
 
e.          Aggregated information                 1,910 
              *    Aggregated volume                GBP15.07534 
                                                    GBP28,793.90 
 
              *    Price 
 
 
              *    Aggregated total 
f.    Date of the transaction                      2021-09-29 
g.    Place of the transaction                     London Stock Exchange, Main Market (XLON) 
 

The issued share capital of the Group is 86,075,856 Ordinary Shares.

-Ends-

 
 For further information, please contact: 
  Oxford Biomedica plc:                      Tel: +44 (0)1865 783 000 
   Natalie Walter, Company Secretary 
 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector(R)), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics and Boehringer Ingelheim, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally, the Group has signed a three-year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 740 people. Further information is available at www.oxb.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHSELFMUEFSEDU

(END) Dow Jones Newswires

September 29, 2021 12:35 ET (16:35 GMT)

Grafico Azioni Oxford Biomedica (LSE:OXB)
Storico
Da Feb 2024 a Mar 2024 Clicca qui per i Grafici di Oxford Biomedica
Grafico Azioni Oxford Biomedica (LSE:OXB)
Storico
Da Mar 2023 a Mar 2024 Clicca qui per i Grafici di Oxford Biomedica